trial
as of 2026-07-01A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
NCTId NCT03382639
at a glance
Phase 2 · Completed
Enrollment 256 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2020-12-29
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
256 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-01-04
Primary completion
2020-12-29
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
Neurocrine BiosciencesLead Sponsor
TakedaCollaborator
Sites
54 total
Garden Grove, United StatesLemon Grove, United StatesLos Angeles, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesNew Haven, United StatesAtlanta, United StatesAugusta, United StatesIndianapolis, United StatesGaithersburg, United StatesGrand Rapids, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
256
Phase
PHASE2
Primary Completion Date
2020-12-29
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
indication
indication